COST

988.57

+0.78%↑

PG

154.96

+0.97%↑

KO

70.77

+0.68%↑

PM

170.36

+0.08%↑

PEP

144.92

-0.21%↓

COST

988.57

+0.78%↑

PG

154.96

+0.97%↑

KO

70.77

+0.68%↑

PM

170.36

+0.08%↑

PEP

144.92

-0.21%↓

COST

988.57

+0.78%↑

PG

154.96

+0.97%↑

KO

70.77

+0.68%↑

PM

170.36

+0.08%↑

PEP

144.92

-0.21%↓

COST

988.57

+0.78%↑

PG

154.96

+0.97%↑

KO

70.77

+0.68%↑

PM

170.36

+0.08%↑

PEP

144.92

-0.21%↓

COST

988.57

+0.78%↑

PG

154.96

+0.97%↑

KO

70.77

+0.68%↑

PM

170.36

+0.08%↑

PEP

144.92

-0.21%↓

Search

Hims & Hers Health Inc

Geschlossen

BrancheKonsumgüter defensiv

49.88 -3.76

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

49.55

Max

51.46

Schlüsselkennzahlen

By Trading Economics

Einkommen

23M

49M

Verkäufe

105M

586M

KGV

Branchendurchschnitt

91.812

26.17

Gewinnspanne

8.444

Angestellte

1,637

EBITDA

48M

66M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

-1.17% downside

Dividenden

By Dow Jones

Nächstes Ergebnis

3. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

5B

14B

Vorheriger Eröffnungskurs

53.64

Vorheriger Schlusskurs

49.88

Nachrichtenstimmung

By Acuity

50%

50%

62 / 150 Ranking in Consumer defensive

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Hims & Hers Health Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Aug. 2025, 00:05 UTC

Heiße Aktien

Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl

29. Apr. 2025, 12:54 UTC

Wichtige Markttreiber

Hims & Hers Rallies After Novo Nordisk Deal on Wegovy

4. Apr. 2025, 22:38 UTC

Heiße Aktien

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

1. Apr. 2025, 23:15 UTC

Wichtige Markttreiber

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

25. Feb. 2025, 15:33 UTC

Wichtige Markttreiber

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

18. Nov. 2024, 19:07 UTC

Wichtige Markttreiber

Hims & Hers Stock Climbs After Former Regulator Autor Joins Board

14. Okt. 2024, 15:02 UTC

Wichtige Markttreiber

Hims & Hers Health Shares Jump After FDA Set to Reconsider Limits on Knockoff Weight-Loss Drugs

5. Aug. 2025, 20:44 UTC

Ergebnisse

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5. Aug. 2025, 18:17 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5. Aug. 2025, 17:26 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Hims & Hers Had a Tough Quarter. Weight-Loss Drugs Are Only One Problem. -- Barrons.com

5. Aug. 2025, 15:25 UTC

Ergebnisse

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5. Aug. 2025, 11:27 UTC

Ergebnisse

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5. Aug. 2025, 10:55 UTC

Ergebnisse

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5. Aug. 2025, 10:36 UTC

Ergebnisse

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

29. Juli 2025, 16:55 UTC

Ergebnisse

The Obesity Bubble Has Finally Burst. Novo Nordisk Shares Drop 21%. -- Barrons.com

24. Juni 2025, 10:26 UTC

Market Talk

Novo Nordisk Sends Clear Message on Copycat Drugs -- Market Talk

3. Juni 2025, 15:03 UTC

Akquisitionen, Fusionen, Übernahmen

Hims & Hers Seeks Growth in Europe as Weight-Loss Business Shifts -- Barrons.com

7. Mai 2025, 13:56 UTC

Ergebnisse

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

6. Mai 2025, 14:24 UTC

Ergebnisse

Hims & Hers Stock Is Higher After Earnings. The Sales Outlook Looks Low. -- Barrons.com

30. Apr. 2025, 09:30 UTC

Top News

Why New Wegovy Deals Won't Restore Novo's Obesity Lead -- Heard on the Street -- WSJ

2. Apr. 2025, 16:53 UTC

Top News

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

19. März 2025, 15:54 UTC

Top News

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

21. Feb. 2025, 23:20 UTC

Ergebnisse

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

10. Feb. 2025, 12:00 UTC

Top News

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

19. Dez. 2024, 17:16 UTC

Top News

FDA Says Shortage of Eli Lilly's Zepbound is Over, But Gives Compounders a Grace Period -- Barrons.com

19. Dez. 2024, 15:14 UTC

Top News

Eli Lilly's Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

19. Dez. 2024, 15:02 UTC

Top News

The Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

16. Dez. 2024, 13:47 UTC

Top News

The Weight-Loss Drug Market Is Heading for a Reckoning This Week -- Barrons.com

16. Dez. 2024, 07:00 UTC

Top News

The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect. -- Barrons.com

3. Okt. 2024, 14:45 UTC

Top News

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

Peer-Vergleich

Kursveränderung

Hims & Hers Health Inc Prognose

Kursziel

By TipRanks

-1.17% Nachteil

12-Monats-Prognose

Durchschnitt 51.33 USD  -1.17%

Hoch 85 USD

Tief 28 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Hims & Hers Health Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

11 ratings

3

Buy

6

Halten

2

Sell

Technischer Score

By Trading Central

36.685 / 52.35Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

62 / 150 Ranking in Konsumgüter defensiv

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Hims & Hers Health Inc

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.